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 1 
INTRODUCTION  2 
 3 
Improvements in breast cancer survival resulting from earlier diagnosis and 4 
advances in therapy have refocused efforts towards reducing the long-term sequelae of 5 
cancer treatment. Persistent or chronic post-surgical pain (CPSP) is a well-recognised 6 
adverse event, with prevalence studies suggesting up to half of women report pain persisting 7 
for 1 to 2 years after breast cancer surgery [1; 20]. We previously reported on the long-term 8 
prognosis and impact of persistent pain after mastectomy, whereby half of women reporting 9 
chronic pain at 3 years postoperatively continued to experience painful symptoms up to 12 10 
years postoperatively, with associated reduced quality of life compared to those whose 11 
chronic pain had resolved [30; 50].  12 
Recent research has focused attention upon the identification of subgroups at 13 
greatest risk of adverse painful outcomes, with calls made for prospective surgical studies 14 
incorporating detailed assessment of multiple factors at repeated time points [24; 28; 54]. 15 
Epidemiological studies with larger sample sizes are required to elucidate the relative 16 
contribution of psychosocial and clinical risk factors for acute pain onset and pain chronicity.   17 
Current thinking, supported by empirical evidence, accepts that CPSP is 18 
predominantly, but not entirely, neuropathic in character. A recent review suggested that 19 
two-thirds of women with CPSP after breast cancer surgery experience neuropathic pain, 20 
although this judgement was retrospectively applied to older studies undertaken before the 21 
development of standardised neuropathic assessment instruments [21]. To date, no studies 22 
have assessed the contribution of preoperative neuropathic pain to CPSP after breast 23 
cancer surgery; it is theoretically plausible that women experience continuation of pre-24 
existing painful symptoms. No large-scale epidemiological studies have accounted for the 25 
contribution of intraoperative nerve handling, as a potential risk factor or effect modifier, to 26 
pain development. In breast cancer surgery, the intercostobrachial nerve (ICBN) can be 27 
sacrificed during axillary dissection for lymph node sampling or clearance, but there is lack of 28 
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agreement regarding attribution of postoperative chest and upper arm pain to intraoperative 1 
nerve damage [18; 33; 45]. Despite changes in surgical technique with increasing rates of 2 
breast conservation surgery and sentinel lymph node biopsy (SLNB), the proximity of the 3 
ICBN to surgical incision and sentinel node(s) may result in nerve irritation, damage or 4 
division, potentially contributing to subsequent postoperative sequelae.  Acute postoperative 5 
numbness and sensory abnormalities may mask painful symptoms that subsequently 6 
become apparent after wound and tissue healing.  7 
 8 
Depression, pain catastrophizing and psychological distress are associated with established 9 
CPSP and predict acute postoperative outcome when measured preoperatively. Certain 10 
psychological traits, such as dispositional optimism, appear to be protective, predicting 11 
improved recovery and a range of favourable postoperative outcomes [38; 39; 48]. We have 12 
previously reported acute postoperative pain outcomes from our prospective epidemiological 13 
study of women undergoing surgery for breast cancer; chronic preoperative pain and 14 
dispositional psychological robustness were independent predictors of severe acute pain in 15 
the first week after surgery [11]. Our primary aim, herein reported, was to investigate the 16 
relative contribution of psychological, sociodemographic, perioperative and acute 17 
postoperative factors associated with the persistence of pain at 4 and 9 months after breast 18 
cancer surgery.  19 
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 1 
METHODS 2 
 3 
Study design and participants  4 
The Study of Recovery after Breast Cancer Surgery (The Recovery Study) was an 5 
epidemiological, prospective cohort study that recruited women from four breast cancer 6 
units, serving a large catchment population across the North of Scotland. Study methodology 7 
and calculation of sample size has been fully described in a previous publication [11]. In 8 
brief, we aimed to recruit 405 women  aged 18 years or over, with newly diagnosed, 9 
histologically proven primary invasive or non-invasive breast cancer, requiring surgical 10 
excision of tumour with or without axillary surgery. Males, women aged <18 years, pregnant 11 
women and those with a history of major psychiatric disorder, previous breast or axillary 12 
surgery, bilateral surgery, recurrent disease or detectable metastatic disease at the time of 13 
initial diagnosis, were excluded.  14 
 15 
Recruitment procedure  16 
Participant recruitment and consent was undertaken at breast clinics and screening centres 17 
or on the hospital ward when patients were admitted prior to surgery. Clinical or research 18 
staff invited patients to participate and provided packs containing an information sheet, 19 
consent form and baseline questionnaire. Consent was obtained for access to medical 20 
records for research purposes.  Ethical approval was granted by Fife and Forth Valley 21 
National Health Service (NHS) Multicentre Research Ethics Committee with local 22 
governance approvals obtained from each regional NHS organisation.  23 
 24 
Data collection  25 
Data collection was undertaken at four time points: preoperatively, and at 1 week, 4 and 9 26 
months postoperatively. Questionnaires and data collection tools were modelled on our 27 
previous studies investigating CPSP and informed by literature review [2; 9; 30; 43; 50]. 28 
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Instruments were piloted on a sample of women to assess face validity. Sociodemographic 1 
variables including age, marital status, highest educational qualification achieved, 2 
employment status and residential location, were measured preoperatively by questionnaire.  3 
Social deprivation was captured using a geographical-based relative measure of deprivation 4 
based upon postcode: participants were allocated to a Scottish Index of Multiple Deprivation 5 
(SIMD) quintile, whereby 1 equates to most deprived, and 5, most affluent) [11].  6 
 7 
Preoperative Pain  8 
Preoperative pain history, incorporating pain character, location and duration of any existing 9 
pain was assessed by self-completion questionnaire. The International Association for the 10 
Study of Pain (IASP) definition of continuous or intermittent pain lasting for 3 months or 11 
longer was used to define chronicity of preoperative pain [22]. Participants reporting any 12 
ache, pain, discomfort, altered sensations or numbness experienced in the previous week 13 
were asked to complete upper body maps, pain-related symptom grids and validated 14 
neuropathic pain instruments. Upper body diagrams were modified from standard 4-view 15 
body diagrams widely used in chronic pain research. Pain diagrams were redrawn to 16 
illustrate different positions, including arms raised, to allow reporting of location of reported 17 
symptoms. Neuropathic pain scales included the Self-completed Leeds Assessment of 18 
Neuropathic Symptoms and Signs pain scale (S-LANSS) [3; 4], the ‘Douleur Neuropathique 19 
4’ (DN4) questionnaire [6] and the Brief Pain Inventory [13]. The S-LANSS and DN4 have 20 
been used in epidemiological surveys, whereby scores of >12 and >3 respectively are 21 
indicative of pain with neuropathic characteristics.  22 
 23 
Given that preoperative investigative tests can cause pain and restrict function, we assessed 24 
arm morbidity before surgery using the Functional Assessment of Cancer Therapy-Breast 25 
questionnaire (FACT-B+4) arm subscale [14]. This scale captures ipsilateral and 26 
contralateral swelling/tenderness, numbness, painful movement, poor range of movement 27 
and stiffness in arm/side of planned breast surgery. Lower scores indicate greater arm 28 
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morbidity (range 0-20). A chronicity question was added to distinguish pain potentially arising 1 
from diagnostic/investigative tests (e.g. fine needle biopsy) from chronic symptoms: 2 
participants were asked whether preoperative painful symptoms had lasted for more than 3 3 
months before surgery. 4 
 5 
Preoperative comorbidity and Quality of Life 6 
Participants were asked to report existing co-morbidity, selecting from a predetermined list of 7 
15 medical conditions. Of these, 10 conditions were considered to be ‘painful’ (e.g. migraine, 8 
angina, back problems, peripheral neuropathy etc). Quality of life was captured using the 9 
EORTC QLQ-C30 questionnaire [16].  10 
 11 
Psychological variables  12 
Standardised instruments were used to measure psychological vulnerability (anxiety, 13 
depression, pain catastrophizing and surgical worry); and protective/ resilience factors 14 
(positive affect and dispositional optimism) before surgery. The State Trait Anxiety Inventory 15 
(STAI) measures state and trait anxiety whereby higher scores indicate greater anxiety 16 
(range 20-80) [51]. The Hospital Anxiety and Depression Scale (HADS) depression sub-17 
scale was used to capture anxious and depressed mood, with higher scores indicating 18 
poorer mental health (range 0-21) [56]. The 13-item Pain Catastrophizing Scale (PCS) was 19 
used to capture pain catastrophizing, defined as an exaggerated negative orientation to 20 
aversive stimuli [37]. Total PCS scores range from 0-52 with higher values indicating greater 21 
catastrophizing. Worry about forthcoming breast surgery was captured using a single item 22 
asking women to rate ‘how worried you are about your operation’ (4-category response) 23 
modified from previous studies [7]. The full Positive and Negative Affect Scale (PANAS) was 24 
used to capture affect, with higher scores indicating greater positive affect (range 10-50) 25 
[55]. The timing of the stem question ‘how you generally feel’ was applied. Two indicators of 26 
psychological ‘robustness’ were assessed: the tendency to experience general positive 27 
affect, captured using the positive affect scale of the PANAS (PANAS-PA); and dispositional 28 
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optimism, defined as generalized outcome expectancies that good things, rather than bad 1 
things will happen, measured using the Life Orientation Test (LOT) (scale range 0-32) [23; 2 
46].  3 
 4 
Clinical and surgical variables  5 
Body mass index (BMI) was calculated from height and weight measured on admission for 6 
surgery. Data on tumour grade and status were extracted from medical records. Operative 7 
data were captured on day of surgery and cross-tabulated against medical records. Breast 8 
surgery was categorised as wide local excision (WLE) or mastectomy with or without 9 
immediate reconstruction. Axillary procedures were categorised as sentinel lymph node 10 
biopsy (SLNB), axillary node sample (ANS) or axillary node clearance (ANC).  11 
 12 
Intercostobrachial nerve (ICBN) handling  13 
Nerve handling data were collected intraoperatively or postoperatively. Senior operating 14 
surgeons were asked to record whether or not the ICBN was identified, and, if identified, 15 
whether the nerve was preserved with no apparent damage, preserved with potential 16 
damage, the main trunk was divided or some branches divided and others preserved at the 17 
time of surgery.  Data were analysed as nerve divided or damaged versus nerve preserved 18 
or not identified e.g. due to anatomical variation or surgery not within vicinity of nerve.  19 
 20 
Anaesthetic variables  21 
A pragmatic, open protocol was permitted for anaesthetic regimes. General anaesthesia was 22 
induced with propofol and fentanyl or alfentanil with volatile maintenance using isoflurane, 23 
sevoflurane or desflurane together with nitrous oxide or air. Intraoperative morphine up to 24 
10mg intravenous was used for mastectomy or axillary clearance, with bupivacaine 25 
infiltration of the breast around the site of skin incision used for WLE’s at the end of 26 
surgery. Bupivacaine infiltration was also administered to the axillary wound following ANS 27 
or SLNB. Usual analgesia included intravenous paracetamol (1g) and 10mg or 30mg IV 28 
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ketorolac, dependent upon age and comorbidity. Postoperative analgesia was 1g 1 
paracetamol 6-8 hourly as required.   2 
 3 
Radiotherapy, Chemotherapy and Endocrine 4 
Treatment regimens accorded with local and national guidelines.  Data on chemotherapy, 5 
radiotherapy and endocrine therapy were extracted from medical records using piloted data 6 
extraction forms. Patients who had breast conservation surgery always underwent 7 
radiotherapy to the breast; those who had undergone mastectomy only received 8 
radiotherapy to the chest wall if there was deemed to be an increased risk of local 9 
recurrence. Patients with an involved sentinel lymph node or positive axillary sample 10 
underwent either axillary radiotherapy or a surgical axillary clearance. Patients with grade III 11 
tumours or those with positive lymph nodes received a standard anthracycline-based 12 
chemotherapy of 6 cycles at three weekly intervals postoperatively. Radiation therapy and 13 
chemotherapy, when administered, were commenced within 4 months of surgery.  14 
 15 
Patients with hormone receptor positive tumours received Tamoxifen if premenopausal, or if 16 
post-menopausal, received an aromatase inhibitor if at an increased risk of recurrence (e.g. 17 
grade III, large primary tumour size or lymph node positive disease) for five years. Those 18 
patients undergoing chemotherapy and whose tumours overexpressed HER2 received 19 
adjuvant trastuzumab for a 12 month period. 20 
 21 
Acute postoperative pain  22 
Acute postoperative pain character at the wound or related area was captured using the 23 
following pain descriptors: ‘ache, pain, discomfort, altered sensations or numbness’ [11]. 24 
These descriptors were based upon the literature and from our previous qualitative 25 
interviews with women reporting chronic post-mastectomy pain [2; 30; 50]. Participants were 26 
asked to select the ‘best’ descriptor for their most painful wound or area. Presence of 27 
numbness and altered sensations in the first week after surgery were considered 28 
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neuropathic-type symptoms. Pain intensity at rest and evoked by movement was captured 1 
using a numerical rating scale (NRS 0-10), administered by telephone on the 7th 2 
postoperative day. 3 
 4 
Definition of chronic pain  5 
Incidence of chronic pain at 4 and 9 months, was defined as any ache, pain, discomfort, 6 
altered sensation or numbness in the upper body, first present after the primary breast 7 
operation and reported to have been present in the week prior to questionnaire completion. 8 
We selected a timeframe of 4 months postoperatively rather than the generally accepted 3 9 
month period to define postoperative pain chronicity, to account for the likelihood that other 10 
active adjuvant treatment may still have been underway at 3 months. Women reporting 11 
chronic pain at follow-up were asked about analgesic use in the previous 24 hours and use 12 
of alternative therapies. They were also asked whether they thought their symptoms were 13 
due to their breast surgery.  14 
 15 
Statistical Analysis  16 
The primary research aim was to identify psychological, sociodemographic and acute 17 
postoperative factors associated with chronic pain at 4 and 9 months after surgery. Initial 18 
analyses were conducted to compare women with and without chronic pain at 4 and at 9 19 
months postoperatively. These unadjusted analyses were treated as exploratory and no 20 
adjustment was made for repeated testing.  For continuous variables, the independent 21 
samples t-test or Mann-Whitney test was used, depending on whether data were normally 22 
distributed. For unordered and ordered categorical variables, the chi-squared test with 23 
continuity correction and the chi-squared test for trend were used respectively.  24 
 25 
Two multiple logistic regression models were then developed to predict chronic pain status 26 
(presence or absence of chronic pain) at 4 and 9 months after controlling for other variables.  27 
Included variables were specified a priori by the Study Group, based upon previous 28 
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literature: age; type of breast surgery (mastectomy or wide local excision); type of axillary 1 
surgery; whether the ICBN was divided or damaged; having more than one breast or axillary 2 
procedure (a second procedure in relation to the primary surgery); presence of preoperative 3 
chronic pain, pain at rest in the first postoperative week; presence of altered sensations or 4 
numbness on the 7th postoperative day, and adjuvant therapy (chemotherapy, radiotherapy 5 
and endocrine therapy).  As described previously [11], many of the psychological variables 6 
were correlated, therefore a factor analysis of preoperative psychological measures (STAI, 7 
HADS depression, PCS, PANAS positive affect, LOT and surgical worry) was used to 8 
reduce these to a smaller number of variables.  The exploratory factor analysis approach 9 
was used using principal component analysis with promax rotation and Kaiser normalisation. 10 
The Eigenvalues and scree plot suggested a single derived component which was given the 11 
label “psychological robustness” because it was particularly associated with higher values of 12 
PANAS-PA and LOT dispositional optimism, also lower values of STAI trait anxiety and 13 
HADS depression. This single variable therefore represented low levels of psychological 14 
vulnerability factors and high levels of psychological resilience factors. The component was 15 
termed psychological robustness because it appeared to fit with broader dimensions of 16 
resources that characterise psychological positivism, combining a ‘habitual style of 17 
anticipating favourable outcomes’ [11; 47].   18 
 19 
Our a priori analysis was based on ‘any’ chronic pain after breast cancer surgery. An 20 
additional secondary analysis was conducted to explore the magnitude and potential impact 21 
of clinically meaningful chronic pain. Using a threshold of >4 on the BPI pain intensity 22 
question (0-10 NRS), we used logistic regression models to investigate risk factors predictive 23 
of moderate to severe chronic pain intensity at 4 and 9 months postoperatively. 24 
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 1 
RESULTS 2 
 3 
The full sample size was achieved, with 406 women being recruited from participating breast 4 
cancer units across Northern Scotland. Forty-four women (10.8%) were excluded after 5 
recruitment and a further 20 women were excluded or withdrawn at different stages during 6 
follow-up, therefore sample size varied by time point.  Preoperative data were available for 7 
362 women, complete acute pain data for 338, 4 and 9 month chronic pain data for 308 and 8 
293 women respectively (Figure 1). Study retention rates were high, with 89% and 87% of 9 
questionnaires returned at 4 and 9 months respectively.  10 
 11 
Median (IQR) time from completion of the baseline questionnaire to surgery was 1 day (1-4 12 
days); 90% of women underwent surgery within two weeks of completion of the baseline 13 
questionnaire. Time from surgery to acute pain assessment was median 8 days (IQR 7-10), 14 
with subsequent follow-up at 4 months (IQR 16.6-19.4 weeks) and 9 months (IQR 38.7-41.4 15 
weeks).  Sociodemographic, surgical and psychological characteristics for the full sample 16 
are presented in Table 1.  17 
 18 
Preoperative pain  19 
Overall, 151/362 (42%) reported painful symptoms in the upper body in the week before 20 
surgery. Of these, a subset of women, 56/362 (15%) had chronic painful symptoms in the 21 
upper body persisting for 3 months before breast surgery, suggesting that the remainder had 22 
pain potentially related to preoperative core biopsy.  Prevalence of preoperative chronic pain 23 
of predominantly neuropathic origin was low: 8/362 (2%) were S-LANSS positive and 12/362 24 
(3%) DN4-positive. Location of chronic symptoms included the breast or breast area, axilla 25 
and/or upper arm (Table 2).  26 
 27 
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 1 
Incidence of chronic pain  2 
Using the primary study definition, 210/308 (68%) women reported chronic pain at 4 months 3 
and 184/293 (63%) at 9 months respectively. Rates are based on any symptom of ache, 4 
pain, discomfort, altered sensation or numbness in the upper body, experienced in the 5 
previous week, but absent before breast cancer surgery. Relaxing the stipulation that painful 6 
symptom(s) were experienced in the previous week, 255/308 (83%) and 235/293 (80%) 7 
women reported any chronic pain at 4 and 9 months respectively. Symptom onset was 8 
variable, with only half of women (54%) being aware of pain-related symptoms in the first 9 
postoperative week (Table 3). The pattern of symptoms, in terms of location and frequency, 10 
was relatively stable rather than dynamic, when compared across follow-up time points. By 9 11 
months postoperatively, more than half of women felt that their symptoms were unchanged, 12 
rather than improving over time (Table 3). Regarding symptom attribution, breast surgery 13 
was reported to be the cause of symptoms for 94% women with chronic pain at 4 months 14 
and 89% of women at 9 months after surgery.    15 
 16 
Pain intensity and character 17 
Most women reported chronic pain of mild intensity (Table 4). Incidence of moderate to 18 
severe/unbearable chronic pain was 23% (47/202) and 27% (49/183) amongst those 19 
reporting chronic pain at 4 and 9 months respectively. Only a small proportion of those with 20 
chronic pain reported having taken analgesics in the previous 24 hours (38% and 22% at 4 21 
and 9 months respectively). At 4 months after surgery, only 7% of women had tried 22 
alternative therapies for their pain; by 9 months postoperatively this had increased slightly to 23 
11%. At 4 and 9 months postoperatively, approximately 40% of those with persistent pain 24 
had neuropathic characteristics, categorised as S-LANSS or DN4-positive (Table 4).  Using 25 
the full postoperative sample as denominator, incidence of predominantly neuropathic pain 26 
was 26% and 24% at 4 and 9 months respectively (81/308; 69/293).  27 
 28 
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Predictors of chronic pain at 4 and 9 months, unadjusted analysis   1 
Table 5 presents preoperative, perioperative and postoperative variables for women with 2 
and without chronic pain at 4 and 9 months.  Women experiencing chronic pain at 4 months 3 
were younger, had axillary node clearance, had ICBN division or damage and were more 4 
likely to have received chemotherapy.  They were also more likely to report more severe 5 
pain, altered sensations or numbness in the first postoperative week.  Factors with a 6 
statistically significant association with chronic pain at 9 months included younger age, 7 
intraoperative ICBN division or damage, having mastectomy, having axillary node clearance, 8 
and having received chemotherapy. 9 
 10 
Preoperative quality of life, arm morbidity and psychological factors were associated with 11 
chronic pain at either 4 or 9 months.  Chronic pain at 4 months was associated with worse 12 
preoperative scores on the FACT-B+4 arm morbidity scale, HADS anxiety, STAI trait 13 
anxiety, negative affect (PANAS), pain catastrophizing and surgical worry.  Preoperative 14 
quality of life, arm morbidity, HADS depression, pain catastrophizing and anxiety (HADs and 15 
STAI-state) were significantly associated with chronic pain at 9 months.  16 
 17 
Predictors of chronic pain at 4 and 9 months, adjusted analysis   18 
Nine variables were included in the multiple logistic regression models predicting chronic 19 
pain at 4 and 9 months.  In the adjusted analysis, there was evidence that younger women, 20 
those with greater preoperative psychological vulnerability and decreased psychological 21 
robustness, and higher acute pain scores at rest in the first postoperative week were more 22 
likely to have chronic pain at 4 months (Table 6).  At 9 months, younger women, those 23 
undergoing axillary node clearance and those with more severe pain at rest in the first 24 
postoperative week were more likely to have persistent chronic pain.  25 
 26 
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Predictors of moderate to severe chronic pain at 4 and 9 months, adjusted analysis   1 
Logistic regression analyses, adjusted for the predetermined clinical, psychological and 2 
sociodemographic factors, revealed that more severe pain at rest within the first week of 3 
surgery was associated with clinically meaningful pain of moderate to severe intensity at 4 4 
months postoperatively (Table 7). Decreased psychological robustness, type of axillary 5 
surgery and more severe acute postoperative pain at rest increased the risk of experiencing 6 
moderate to severe pain at 9 months postoperatively. Several risk factors were of borderline 7 
statistical significance: younger age and having had multiple surgical procedures were 8 
associated with greater pain intensity at 4 months, and chronic preoperative pain was 9 
associated with greater pain intensity at 9 months postoperatively.  10 
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 1 
DISCUSSION  2 
This multicentre prospective cohort study investigated psychological, sociodemographic, and 3 
surgical risk factors, adjusted for intraoperative nerve handling, on painful adverse outcomes 4 
captured at multiple time points after resectional surgery for primary breast cancer.   5 
 6 
We found a high incidence of chronic pain, with two-thirds of women reporting pain-related 7 
symptoms in the upper body region, 4 and 9 months after surgery. There was little change in 8 
the proportion reporting chronic persistent pain over time. Rather than restricting our 9 
definition to pain per se, our broad definition also accepted any ache, discomfort, altered 10 
sensations or numbness in the area of surgical incision that was not present preoperatively; 11 
this may account for the high incidence. Other population surveys accept any ‘aches or 12 
pains’ within definitions of regional or widespread pain [31]. We deliberately included 13 
nociceptive pain descriptors (ache/discomfort), to identify whether postoperative non-14 
neuropathic symptoms are associated with later functional impairment and long-term pain-15 
related disability. One recent Danish survey found that 50% of women reported ‘sensory 16 
disturbances’ (yes/no) at 5 to 7 years postoperatively [34], although no preoperative 17 
assessment was undertaken. We captured pre- and postoperative altered sensations and 18 
numbness by location and investigated whether acute postoperative symptoms predicted 19 
painful symptoms later in the recovery timeline. Indeed, acute postoperative numbness and 20 
altered sensations were associated with chronic pain at 4 and 9 months, but were not 21 
statistically significant after adjustment for other factors, nor were they predictive of pain 22 
intensity. A quarter of women experienced pain of moderate or severe intensity and 40% 23 
screened positive on DN4 and S-LANSS.  24 
 25 
At 4 months, younger age and acute postoperative pain were independent predictors of 26 
CPSP, as was our composite variable representing psychological robustness, which was 27 
associated with a 30% reduction in the odds of reporting CPSP. Severity of acute pain 28 
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predicted moderate to severe chronic pain at 4 and 9 months. Evidence that sensory 1 
abnormality immediately after surgery may predict long-term adverse outcome is scant, but 2 
emerging: neuropathic characteristics occurring within 2 days of thoracic surgery predicted 3 
chronic neuropathic pain at 3 months postoperatively [49].  4 
 5 
At 9 months, CPSP was 3 times more likely after axillary clearance, with younger age and 6 
acute postoperative pain also associated with persistent pain. Younger age independently 7 
predicted CPSP and pain intensity at 4 months; this finding differs from previous work 8 
whereby younger women were more likely to report clinically meaningful pain in the acute 9 
postoperative period, but not by 3 months postoperatively [41]. Explanations for this finding 10 
may relate to increased expectation related to functional recovery or may be biological, with 11 
younger patients potentially having more heightened central nervous system responsiveness 12 
[34]. Younger age has been associated with CPSP in numerous other surgical procedures, 13 
[27; 40; 42], although studies of breast cancer surgery are less conclusive [8; 20; 34; 50; 53]. 14 
Younger women are more likely to have a higher histopathological tumour grade and 15 
undergo more aggressive adjuvant treatment, particularly chemotherapy [29]. Unadjusted 16 
analyses suggested that chemotherapy was associated with chronic pain at 4 and 9 months, 17 
however, this relationship was attenuated after adjustment. We found no evidence of 18 
increased risk of CPSP associated with adjuvant therapy; this finding is comparable with 19 
other literature [17; 41], although the large national Danish study identified a relationship 20 
between chronic pain and radiotherapy, but not site of radiotherapy [20].  21 
 22 
Increased psychological distress, captured using scales assessing emotions and cognition, 23 
was predictive of moderate to severe acute postoperative pain and chronic pain intensity. 24 
The few prospective studies investigating psychological status before breast cancer surgery 25 
have focused upon individual distress variables e.g. anxiety, depression, catastrophizing  26 
[25; 40], rather than more general emotional and cognitive resilience. We explored the role 27 
of psychological robustness to investigate resilience and capacity to withstand adverse 28 
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circumstances when faced with a potentially life threatening illness and pending surgery. Our 1 
study is novel in examining the role and contribution of both negative and positive 2 
psychological states on pain outcomes after breast cancer surgery. Psychological 3 
robustness indicates the adoption of positive coping strategies in the face of external threats 4 
and suggests a positive postoperative recovery trajectory [12]. Katz [24] reasonably argues 5 
that different risk factors may contribute to the onset and maintenance of pain; indeed, we 6 
found that our derived variable, psychological robustness was protective earlier in the 7 
recovery trajectory, and although a similar effect size was found at 9 months, this did not 8 
maintain significance in multivariate analysis.  9 
 10 
We hypothesized that apparent ICBN damage would predict CPSP. Nerve injury is 11 
necessary, but not sufficient for the development of chronic postoperative neuropathic pain 12 
[32]. Findings from small clinical trials of ICBN division have been contradictory: one found a 13 
greater degree of postoperative numbness, pain severity and arm stiffness after ICBN 14 
division during axillary dissection, compared with nerve preservation [33]. Conversely, 15 
another study concluded that nerve preservation was unnecessary as there was no 16 
difference in postoperative functional outcome after nerve division or preservation [45]. 17 
Studies of ICBN handling are methodologically weak, either hampered by small sample size 18 
or lacking in preoperative pain characterisation. Breast conserving surgery is less invasive 19 
than mastectomy, with lower risk of tissue damage, although ICBN irritation may still occur. 20 
We adjusted for type of axillary surgery, distinguishing between the extent of axillary surgery 21 
performed. Previous studies have categorised surgery as lumpectomy/mastectomy with or 22 
without axillary node surgery [41], whereas our more refined classification highlights the 23 
extent of axillary node surgery performed. The practice of axillary node clearance is 24 
decreasing but is still appropriate for patients with axillary node involvement.   25 
 26 
One methodological and clinical challenge, hitherto not acknowledged in previous studies of 27 
CPSP after breast surgery, was the high rate of second operations on the breast, particularly 28 
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in women undergoing breast conservation surgery.  The need for secondary procedures 1 
(usually to excise margins in those undergoing breast conservation surgery or to undertake 2 
mastectomy when conservation surgery has been attempted but adequate tumour clearance 3 
has not been achieved), is well acknowledged within surgical oncology but not in the pain 4 
literature. One US centre reported that approximately half of women required repeat surgery 5 
for margin or axillary clearance because of a staging procedure (axillary sample or SLNB) 6 
having shown axillary nodal involvement by tumour [36].   We found a marginal association 7 
between repeat surgery and moderate to severe chronic pain at 4 months. Central 8 
sensitization may reflect both neuropathic mechanisms associated with nerve injury and 9 
inflammatory processes associated with the surgical wound [8; 26; 27]. It ishighly plausible 10 
that repeated surgical insult to a previously inflamed area may heighten CNS 11 
responsiveness and contribute to central sensitization.  This is an area worthy of future 12 
investigation.  13 
 14 
Our study is limited by number of participants but our sample is geographically 15 
representative of the Northern and Eastern Scotland, incorporating remote-rural, urban and 16 
socially diverse populations. We did not adjust for pain treatment modalities because 17 
perioperative analgesia regimes were standardised, however, this may impact upon pain 18 
reporting. Given the epidemiological design, we accepted self-reported neuropathic 19 
characteristics without confirmation by clinical examination as this was impractical to achieve 20 
on a large, geographically scattered population. However, evidence suggests good 21 
discriminant ability of neuropathic pain screening tools [5; 6].  22 
 23 
The strengths of our study include being the first epidemiological study to investigate 24 
multiple pain predictors adjusted for intercostobrachial nerve handling. The lack of surgical 25 
pain studies investigating the contribution of nerve handling was recently highlighted in the 26 
BMJ [34]. Participating surgeons were supportive of our study and assisted with the design 27 
of intraoperative data collection forms; we achieved 97% complete data on nerve handling. 28 
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We adjusted for other potential confounding factors, specified a priori, identified from existing 1 
literature and from our own research [9-11; 30; 43; 50; 54]. Other strengths include the 2 
detailed preoperative assessment of baseline health status and pain history, often neglected 3 
from surgical cohort studies [2; 17; 20; 44] and experimental studies incorporating sensory 4 
testing [15; 19; 32]. Identification of preoperative upper body pain provided incidence data 5 
on persistent pain arising as a consequence of surgery and related treatment. As with any 6 
large epidemiological study, we were unable to exclude with absolute certainty that the small 7 
subset reporting chronic preoperative breast pain did not have continuing painful symptoms 8 
rather than surgically-induced incident pain; this can only be attempted by detailed clinical 9 
assessment and investigation at the individual level. However, a compelling finding was that 10 
the majority of women (~90%) attributed breast surgery as the cause of their painful 11 
symptoms after cancer treatment.  12 
CONCLUSION  13 
This study highlights the frequency and persistence of pain-related outcomes as a 14 
consequence of breast cancer treatment and identifies clinical and psychological factors 15 
potentially amenable to intervention. Incidence of pain, altered sensations and numbness is 16 
very high after primary breast cancer surgery, with about one quarter experiencing 17 
neuropathic pain up to 9 months postoperatively. We provide insights into those at risk of 18 
persistent adverse outcomes, namely younger women, those with psychological 19 
vulnerability, axillary clearance surgery and more severe acute postoperative pain. 20 
Preventive strategies should target these risk factors to reduce adverse sequelae of 21 
treatment, supplemented with broader efforts to support the longer term physical and 22 
psychological recovery in cancer survivors.  23 
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Figure 1.  Flow chart of recruited participants 
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Returned 4 month questionnaire (n=310) 
Complete data available (n=308) 
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Table 1: Sociodemographic, surgical and pre-operative psychological characteristics 
[Eligible N=362] 
 Mean (SD) [N] 
Age, years,   59.1 (10.8) [356]  
BMI,  28.0 (5.9) [350] 
 N (%) 
Married  241/362 (66.6) 
  
Highest Educational level  N (%) 
School only  109 (30.3) 
Work or college qualification 180 (50.0) 
Degree qualification  71 (19.7) 
Missing  2 
  
Deprivation score quintile (SIMD) N (%) 
1 (most deprived) 17 (4.7) 
2 35 (9.7) 
3 65 (18.0) 
4 145 (40.1) 
5 (most affluent)  100 (27.6) 
  
Arm morbidity  Median (IQR) [N] 
FACT-B arm subscale  20 (20-20) [361] 
  
Preoperative psychological health Median (IQR) [N] {Cronbach’s α} 
STAI State 40 (30-50) [347] {0.86} 
  
2 
 
STAI Trait  32.5 (26-42) [350] {0.94} 
HADS Anxiety  7 (3-10) [360] {0.89} 
HADS Depression  1.5 (0-4) [360] {0.85} 
LOT  24 (16-32) [345] {0.51} 
 Median (IQR) [N] {Cronbach’s α} 
PANAS Positive  30.5 (4.9) [355] {0.76} 
PANAS Negative 23.0 (4.5) [355] {0.64} 
PCS Total Score  11.0 (9.2) [349] {0.94} 
  
Surgical worry N (%) 
Not at all/a little  221 (61.7) 
Quite a bit/very much  137 (38.3) 
Missing  4 
  
Any painful co morbidity N (%) 
Yes 231 (63.8) 
No 131 (36.2) 
  
Chronic pain (>3 months) before 
surgery* N (%) 
Yes 56 (15.6) 
No 303 (84.4) 
Missing  3 
Breast surgery  N (%) 
WLE  228 (63.9) 
Mastectomy 92 (25.8)  
  
3 
 
Mastectomy with reconstruction 15 (4.2) 
Missing 5 
  
Axillary surgery N (%) 
SLNB 146 (42.1) 
ANS 94 (26.0) 
ANC 107 (29.6) 
Missing  15 
  
ICBN status  N (%) 
Not identified 96 (27.4) 
Preserved  144 (41.1) 
Divided /damaged 110 (31.4) 
Missing 12 
  
Cancer status  N (%) 
Invasive 342 (95%) 
Non-invasive  17 (5%) 
*Including women with ache, pain, discomfort, altered sensations or numbness in the upper 
body in the previous week  
SD: standard deviation; BMI: body mass index; SIMD: Scottish Index of Multiple Deprivation; 
WLE: wide local excision; SLNB: sentinel lymph node biopsy; ANS: axillary node sample; 
ANC: axillary node clearance; FACT: Functional Assessment of Cancer Therapy; IQR: 
interquartile range; STAI: State Trait Anxiety Inventory; HADS: Hospital Anxiety and 
Depression Scale; PANAS: Positive and Negative Affect Scale; PCS: Pain Catastrophizing 
Scale; LOT: Life Orientation Test. Table published [reference 11]  
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Table 2: Location and character of chronic pain and related symptoms* 
 Chronic 
preoperative 
pain 
[N=56] 
Chronic pain  
at 4 months 
 
 [N=210] 
Chronic pain 
at 9 months 
 
 [N=184] 
 n (%) n (%)  n (%) 
Breast or breast area    
Pain 9 (16) 58 (28) 46 (25) 
Ache or discomfort 30 (54) 106 (50) 90 (49) 
Numbness or altered 
sensations 
9 (16) 98 (47) 92 (50) 
Axilla     
Pain 2 (4) 33 (16) 20 (11) 
Ache or discomfort 12 (21) 77 (37) 72 (39) 
Numbness or altered 
sensations 
4 (7) 119 (57) 84 (46) 
Upper arm    
Pain 3 (5) 17 (8) 11 (6) 
Ache or discomfort 10 (18) 39 (19) 46 (25) 
Numbness or altered 
sensations 
5 (9) 99 (47) 79 (43) 
*Symptoms occurred in the last week. Where preoperative, symptoms persisting for at least 
3 months.  Postoperatively, symptoms must be first present after the primary breast 
operation. 
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Table 3:  Onset and pattern of pain-related symptoms 
 Chronic 
pain at 4 
months 
[N=210] 
Chronic pain 
at 9 months 
[N=184] 
n (%)  n (%) 
When did you first notice these symptoms?   
Within the first week  112 (54) n/a 
More than 1 week but within 1 month  61 (29) n/a 
Between 1- 2 months after surgery 19 (9) n/a 
Between 2-4 months after surgery  15  (7) n/a 
More than 4 months after my surgery  n/a 30 (16) 
Not known 3 1 
How often have you had these symptoms?   
Continuously 92 (44) 89 (48) 
Once or more a day 70 (33) 48 (26) 
Once or more a week 38 (18) 36 (20) 
Once or more a month 6 (3) 6 (3) 
Less than once a month 1 (0) 0 
Not known 3 5 
Do you think these symptoms are due to your breast 
surgery?  
  
Yes 194 (94) 158 (89) 
No  13 (6) 20 (11) 
Not known 3 6 
Do you think these symptoms are:   
Getting better 123 (59) 67 (36) 
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Getting worse 7 (3) 11 (6) 
Staying just the same 78 (38) 105 (57) 
Not known 2 1 
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Table 4:  Pain intensity and neuropathic characteristics  
 
 
Preoperative 
chronic pain 
[N=56] 
Chronic pain at  
4 months 
 [N=210] 
Chronic pain at 
9 months 
 [N=184] 
Pain intensity in previous 
week [NRS 0-10]24 hours 
n (%) n (%)  n (%) 
None (0)  3 (5) 28 (14) 27 (15) 
Mild (1-3) 34 (61) 127 (63) 107 (58) 
Moderate (4-7) 15 (27) 44 (22) 43 (23) 
Severe /Unbearable (8-10)  4 (7) 3 (2) 6 (3) 
Missing 2 8 1 
    
BPI  Median (IQR) [N] Median (IQR) [N] Median (IQR) [N] 
BPI Pain severity (4 items) 2 (1-4) [53] 1.25 (0.75-2.75) 
[202] 
1.75 (0.75-3) 
[182] 
BPI Pain intensity (7 items) 1 (0.29-3) [55] 0.43 (0-1.71) 
[206] 
0.43 (0-1.86) 
[183] 
Treatment  N (%) N (%) N (%) 
Taking pain medication  17/56 (30) 46/210 (38) 40/184 (22) 
Tried alternative therapies for 
pain  
10/53 (19) 13/197 (7) 20/174 (11) 
    
S-LANSS   5 (0-18) [55] 11 (0-24) [194] 10 (0-24) [169] 
S-LANSS negative < 12 47 (85) 113 (58) 100 (59) 
S-LANSS positive >12 8 (15) 81 (42) 69 (41) 
Missing 1 16 15 
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DN4    1 (0-7) [51] 2 (0-7) [189]  2 (0-7) [178] 
DN4 negative (%)  39 (76) 114 (60) 105 (59) 
DN4 positive (%) 12 (24) 75 (40) 73 (41) 
Missing 5 21 6 
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Table 5: Sociodemographic, clinical and psychological factors associated with chronic pain at 4 and 9 months after breast cancer 
surgery  
 
  4 months 9 months  
Chronic pain 
(max N=210) 
No chronic 
pain (max 
N=98) 
 Chronic 
pain (max 
N=184) 
No chronic 
pain (max 
N=109) 
 
Mean (SD) [N] Mean (SD) [N] p-value (t-
test) 
Mean (SD) 
[N] 
Mean (SD) 
[N] 
p-value (t-
test) 
Age  57.7 (10.3) [206] 64.1 (9.4) [96] <0.001 58.1 (10.2) 
[181] 
62.3 (10.3) 
[108] 
0.001 
   N (%)  N (%) p-value (χ2 
test) 
 N (%)  N (%) p-value (χ2 
test) 
Marital status Single 13 (65) 7 (35) 1.00 11 (58) 8 (42) 0.39 
 Living with 
partner 
13 (69) 6 (32)  10 (59) 7 (41)  
 Married 142 (69) 64 (31)  121 (61) 78 (39)  
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 Separated 6 (67) 3 (33)  8 (89) 1 (11)  
 Divorced 10 (67) 5 (33)  12 (80) 3 (20)  
 Widowed 26 (67) 13 (33)  22 (65) 12 (35)  
        
   N (%)  N (%) p-value (χ2 
test for 
trend) 
 N (%)  N (%) p-value (χ2 
test for trend) 
SIMD 
Deprivation 
category 
1  
(most deprived) 
5 (42) 7 (58) 0.24 4 (40) 6 (60) 0.60 
 2 22 (69) 10 (31)  20 (59) 14 (41)  
 3 38 (67) 19 (33)  35 (70) 15 (30)  
 4 88 (71) 36 (29)  76 (64) 43 (36)  
 5  
(most affluent) 
57 (69) 26 (31)  49 (61) 31 (39)  
        
Surgical Unit  1 72 (65) 38 (35) 0.49 69 (65) 37 (35) 0.15 
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 2 89 (73) 33 (27)  70 (61) 44 (39)  
 3 21 (68) 10 (32)  23 (77) 7 (23)  
 4 28 (62) 17 (38)  22 (51) 21 (49)  
        
  Mean (SD) [N] Mean (SD) [N] p-value (t-
test) 
Mean (SD) 
[N] 
Mean (SD) 
[N] 
p-value (t-
test) 
Body mass 
index 
 27.8 (5.5) [204] 28.6 (5.8) [94] 0.24 28.1 (5.4) 
[178] 
27.7 (5.5) 
[105] 
0.48 
        
   N (%)  N (%) p-value (χ2 
test) 
 N (%)  N (%) p-value (χ2 
test) 
Any painful 
comorbidity 
preoperatively 
Yes 136 (68) 65 (32) 0.89 59 (57) 44 (43) 0.19 
 No 74 (69) 33 (31)  125 (66) 65 (34)  
Multiple 
procedures 
Yes 49 (77) 15 (23) 0.14 134 (60) 90 (40) 0.08 
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 No 161 (66) 83 (34)  50 (72) 19 (28)  
        
Type of breast 
surgery 
WLE  127 (65) 69 (35) 0.12 108 (57) 82 (43) 0.006 
 Mastectomy 83 (74) 29 (26)  76 (74) 27 (26)  
Type of axillary 
surgery 
ANC  74 (81) 17 (18) 0.006 71 (81) 17 (19) <0.001 
 ANS 54 (63) 32 (37)  41 (52) 38 (48)  
 SLNB  76 (62) 46 (38)  65 (56) 51 (44)  
 Not known 6 3  7 4  
ICBN status Not identified/ 
preserved 
111 (60) 74 (40) <0.001 91 (52) 83 (48) <0.001 
 Divided/ 
damaged 
93 (80) 23 (20)  89 (78) 25 (22)  
 Not known 6 1  4 2  
   N(%)  N(%) p-value (χ2 
test) 
 N(%)  N(%) p-value (χ2 
test) 
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Chemotherapy Yes 80 (76) 25 (24) 0.04 81 (76) 25 (24) <0.001 
 No 130 (64) 73 (36)  103 (55) 84 (45)  
Radiotherapy Yes 106 (69) 48 (31) 0.90 136 (61) 86 (39) 0.41 
 No 104 (68) 50 (32)  48 (68) 23 (32)  
Endocrine 
therapy 
Yes 118 (64) 65 (36) 0.12 144 (62) 90 (38) 0.46 
 No 92 (74) 33 (26)  40 (68) 19 (32)  
        
  Mean (SD) [N] Mean (SD) [N] p-value (t-
test) 
Mean (SD) 
[N] 
Mean (SD) 
[N] 
p-value (t-
test) 
EORTC QLQ-
C30 
Baseline Global 
health status/QoL 
77.4 (18.9) [210] 80.8 (18.3) 
[97] 
0.13 75.7 (19.2) 
[184] 
82.3 (18.1) 
[108] 
0.004 
        
  Median (IQR) 
[N] 
Median (IQR) 
[N] 
p-value 
(Mann-
Whitney) 
Median 
(IQR) [N] 
Median 
(IQR) [N] 
p-value 
(Mann-
Whitney) 
FACT-B+4 Baseline arm 20 (20-20) [210] 20 (20-20) [97] 0.05 20 (20-20) 20 (20-20) 0.02 
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morbidity 
subscale 
[184] [109] 
HADS Baseline 
depression 
2 (0-4) [208] 1 (0-4) [98] 0.20 2 (0-5) [182] 1 (0-3.5) 
[109] 
0.05 
 Baseline anxiety 7 (4-11) [208] 6 (2-8) [98] <0.001 7 (4-11) 
[182] 
6 (2.5-9) 
[109] 
0.003 
STAI Baseline state 
anxiety 
43.3 (30-50) 
[207] 
36.7 (26.7-
48.3) [89] 
0.10 40 (30-50) 
[179] 
36.7 (26.7-
46.7) [102] 
0.03 
 Baseline trait 
anxiety 
33 (27-42) [207] 29 (24-39) [93] 0.01 33 (27-43) 
[179] 
30.5 (25-
39.3) [106] 
0.10 
LOT Baseline 24 (17-31) [200] 24 (16-32) [92] 0.72 24 (16-32) 
[176] 
24 (17-32) 
[104] 
0.65 
Pain 
Catastrophizing 
Score (PCS) 
Baseline total 
score 
10 (5-16) [206] 6 (1-14) [91] 0.005 9 (5-15.8) 
[180] 
7 (3-15.8) 
[104] 
0.07 
  Mean (SD) [N] Mean (SD) [N] p-value (t-
test) 
Mean (SD) 
[N] 
Mean (SD) 
[N] 
p-value (t-
test) 
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PANAS Baseline positive 
affect 
30.4 (5.0) [208] 30.7 (4.9) [95] 0.63 30.4 (4.9) 
[182] 
30.6 (4.9) 
[108] 
0.74 
 Baseline negative 
affect 
23.4 (4.8) [208] 21.8 (3.8) [95] 0.001 23.0 (4.7) 
[182] 
22.3 (4.2) 
[108] 
0.15 
   N(%)  N(%) p-value (χ2 
test for 
trend) 
 N(%)  N(%) p-value (χ2 
test for trend) 
How worried 
about operation 
Not at all 17 (61) 11 (39) 0.03 14 (50) 14 (50) 0.20 
 A little 108 (65) 59 (35)  96 (61) 61 (39)  
 Quite a bit 54 (77) 16 (23)  52 (75) 17 (25)  
 Very much 31 (78) 9 (23)  21 (58) 15 (42)  
 Not known 0 3  1 2  
        
  Mean (SD) [N] Mean (SD) [N] p-value (t-
test) 
Mean (SD) 
[N] 
Mean (SD) 
[N] 
p-value (t-
test) 
Component 1 at “Psychological 0.024 (1.01) -0.293 (1.00) 0.02 -0.002 -0.304 (0.98) 0.02 
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baseline robustness” [193] [81] (0.98) [167] [94] 
        
   N(%)  N(%) p-value (χ2 
test) 
 N(%)  N(%) p-value (χ2 
test) 
Chronic pain at 
baseline 
Yes 39 (83) 8 (17) 0.03 34 (72) 13 (28) 0.18 
 No 169 (65) 90 (35)  149 (61) 96 (39)  
 Not known 2 0  1 0  
        
  Median (IQR) 
[N] 
Median (IQR) 
[N] 
p-value 
(Mann-
Whitney) 
Median 
(IQR) [N] 
Median 
(IQR) [N] 
p-value 
(Mann-
Whitney) 
Acute pain at 
rest*  
 3 (2-5) [199] 2 (1-4) [95] 0.001 3 (2-5) [177] 2 (1-4) [104] 0.11 
   N(%)  N(%) p-value (χ2 
test) 
 N(%)  N(%) p-value (χ2 
test) 
Altered Yes 93 (77) 28 (23) 0.005 81 (69) 36 (31) 0.07 
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sensations or 
numbness 
(acute)** 
 No 106 (61) 69 (39)  96 (58) 70 (42)  
 Not known 11 1  6 3  
 
*Pain at rest in first postoperative week. **First postoperative week.  
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Table 6: Multiple logistic regression models predicting chronic pain at 4 and 9 months  
  Chronic pain at 4 months 
(N=243) 
Chronic pain at 9 months 
(N=235) 
Odds ratio (95% CI) p-value Odds ratio (95% CI) p-value 
Age  0.91 (0.87, 0.95) <0.001 0.95 (0.91, 0.98) 0.002 
      
Type of breast surgery WLE  1 0.44 1 0.88 
 Mastectomy 1.38 (0.60, 3.15)  1.07 (0.43, 2.67)  
      
Type of axillary surgery SLNB  1 0.11 1 0.02 
 ANS  0.70 (0.31, 1.54)  0.62 (0.30, 1.29)  
 ANC  2.40 (0.82, 6.94)  2.97 (1.09, 8.06)  
      
ICBN status Not identified/preserved 1 0.25 1 0.49 
 Divided/damaged 1.72 (0.68, 4.30)  1.35 (0.57, 3.16)  
      
Preoperative chronic pain No 1 0.19 1 0.73 
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 Yes 1.98 (0.71, 5.47)  1.16 (0.50, 2.66)  
      
Preoperative psychological 
robustness* 
 0.70 (0.49, 0.99) 0.04 0.78 (0.56, 1.09) 0.14 
      
Multiple procedures No 1 0.06 1 0.10 
 Yes 2.44 (0.95, 6.24)  2.00 (0.87, 4.57)  
      
Pain at rest in first postoperative 
week (VAS 0-10) 
 1.34 (1.12, 1.60) 0.001 1.17 (1.00, 1.37) 0.05 
      
Numbness / altered sensations 
within first postoperative week  
No 1 0.09 1 0.41 
 Yes 1.80 (0.90, 3.59)  1.31 (0.69, 2.46)  
      
Chemotherapy  No 1 0.05 1 0.60 
 Yes  0.29 (0.81, 1.01)  0.80 (0.35, 1.85)  
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Radiotherapy No 1 0.24 1 0.34 
 Yes  1.69 (0.71, 4.00)  0.62 (0.24, 1.66)  
      
Endocrine therapy No 1 0.19 1 0.99 
 Yes  0.49 (0.17, 1.41)  1.01 (0.45, 2.23)  
*Composite psychological variable based upon factor analysis.  
The model performance was adequate for both logistic regression models (Hosmer and Lemeshow goodness of fit test: χ2=6.11, df=8, p=0.64 
(4 months); χ2=5.73, df=8, p=0.68 (9 months)).   
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Table 7: Multiple logistic regression models predicting chronic pain of moderate to severe intensity (≥4) at 4 and 9 months 
  Moderate to severe chronic pain 
at 4 months 
(N=237) 
Moderate to severe chronic pain 
at 9 months 
(N=234) 
Odds ratio (95% CI) p-value Odds ratio (95% CI) p-value 
Age  0.96 (0.91, 1.00) 0.08 1.00 (0.95, 1.04) 0.82 
      
Type of breast surgery WLE  1 0.75 1 0.47 
 Mastectomy 0.86 (0.32, 2.26)  0.47 (0.17, 1.24)  
      
Type of axillary surgery SLNB  1 0.19 1 0.007 
 ANS  0.41 (0.14, 1.21)  0.31 (0.09, 1.01)  
 ANC  1.25 (0.37, 4.18)  2.72 (0.87, 8.46)  
      
ICBN status Not identified/preserved 1 0.60 1 0.59 
 Divided/damaged 0.75 (0.25, 2.18)  0.76 (0.28, 2.05)  
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Preoperative chronic pain No 1 0.13 1 0.05 
 Yes 2.05 (0.81, 5.16)  2.41 (0.99, 5.87)  
      
Preoperative psychological 
robustness* 
 0.86 (0.58, 1.26) 0.44 0.52 (0.35, 0.77) 0.001 
      
Multiple procedures No 1 0.05 1 0.68 
 Yes 2.77 (0.98, 7.81)  1.25 (0.43, 3.61)  
      
Pain at rest in first postoperative 
week (VAS 0-10) 
 1.54 (1.27, 1.87) <0.001 1.30 (1.08, 1.56) 0.006 
      
Numbness / altered sensations 
within first postoperative week  
No 1 0.66 1 0.21 
 Yes 0.83 (0.36, 1.89)  0.60 (0.26, 1.34)  
      
Chemotherapy  No 1 0.57 1 0.91 
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 Yes  0.62 (0.12, 3.14)  1.10 (0.21, 5.71)  
      
Radiotherapy No 1 0.37 1 0.15 
 Yes  0.60 (0.20, 1.80)  0.47 (0.16, 1.33)  
      
Endocrine therapy No 1 0.59 1 0.77 
 Yes  0.68 (0.16, 2.78)  1.26 (0.27, 5.87)  
*Composite psychological variable based upon factor analysis.  
The model performance was adequate for both logistic regression models (Hosmer and Lemeshow goodness of fit test: χ2=10.05, df=8, p=0.26 
(4 months); χ2=9.39, df=8, p=0.31 (9 months)).   
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ABSTRACT  1 
Chronic post-surgical pain (CPSP) is a common postoperative adverse event affecting up to 2 
half of women undergoing breast cancer surgery, yet few epidemiological studies have 3 
prospectively investigated the role of pre-, intra- and postoperative risk factors for pain onset 4 
and chronicity. We prospectively investigated preoperative sociodemographic and 5 
psychological factors, intraoperative clinical factors and acute postoperative pain in a 6 
prospective cohort of 362 women undergoing surgery for primary breast cancer. 7 
Intraoperative nerve handling (division or preservation) of the intercostobrachial nerve was 8 
recorded. At 4 and 9 months after surgery, incidence of chronic painful symptoms, not 9 
present preoperatively, was 68% and 63% respectively. Univariate analysis revealed that 10 
multiple psychological factors and nerve division was associated with chronic pain at 4 and 9 11 
months. In a multivariate model independent predictors of CPSP at 4 months included 12 
younger age and acute postoperative pain (OR 1.34, 95% CI 1.12, 1.60), whereas 13 
preoperative psychological ‘robustness’ (OR 0.70, 95% CI 0.49, 0.99), a composite variable 14 
comprising high dispositional optimism, high positive affect and low emotional distress, was 15 
protective. At 9 months, younger age, axillary node clearance (OR 2.97, 95% CI 1.09, 8.06) 16 
and severity of acute postoperative pain (OR 1.17, 95% CI 1.00, 1.37) were predictive of 17 
pain persistence. Of those with CPSP, a quarter experienced moderate to severe pain and 18 
40% 25% were positive on DN4 and S-LANSS.  Overall, A high proportion of women report 19 
painful symptoms, altered sensations and numbness, in the upper body within the first 9 20 
months after resectional breast surgery and cancer treatment.   21 
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